PURPOSE: To obtain the subject new compound, having anticomplementary activity and useful for treating nephritis, rheumatism or systemic lupus erythematosus (SLE).
CONSTITUTION: A compound, expressed by formula I, II, etc., and having the following physico-chemical properties: High-resolution mass spectrum (HR-MS); a change is recognized at ≥85°C melting point without showing a definite melting point. Appearance; white powder. Solubility; soluble in alkaline water, methanol, acetone and ethyl acetate. Specific rotatory power; [α]25D=-167.5 (C=0.04, methanol) (Q-11270-A) and -25.53 (C=0.188, methanol) (Q-11270-B). Molecular formula; C28H39NO6 (Q-11270-A), C28H39NO7 (Q-11270-B). Molecular weight; 485 (Q-11270-A), 501 (Q-11270-B), etc. The compound expressed by formula I, II, etc., is obtained by culturing a strain belonging to the genus Stachybotrys such as Stachybotrys chartarum Q11270 (FERM P-12629).
| JP2002201171 | UREACARBOXYLIC ACID DERIVATIVE |
| WO/2011/101816 | AN IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM |
| JP4331264 | Calcium receptor active compound |
NAGAI KOJI
FUKUNAGA YUKIKO
SUGITA YUJI
